FY22 Financial Results & Business Outlook
Filed with ASX · · 9 pages · English
Watch Cogstate's latest callCogstate (ASX:CGS) Q4 2026 Earnings Call · Replay · Aug 17Read the transcript of Cogstate (ASX:CGS) Q4 2026 Earnings Call• Record Group Revenue of $45.0m, up 38% on PCP. • Record Group Earnings: Profit Before Tax (PBT) of $10.7m (vs. guidance of $10.3m - $10.8m and PCP - $5.8m) and Net Profit After Tax (NPAT) of $7.5m (PCP $5.2m)*. • Clinical Trials - Another record-breaking year - Clinical Trials sales contracts executed in FY22 was up 74% on PCP to a record of $82.5m. - Clinical Trials revenue was up 41% on PCP to
In the deck
Story so far
Earlier from Cogstate
- Business Update and June 2022 Quarter Cashflow
- Cogstate Announces Formation of Scientific Advisory Board
- Investor Update
- Business Update and March 2022 Quarter Cashflow
- S&P DJI Announces March 2022 Quarterly Rebalance
Later from Cogstate
- Business Update and September 2022 Quarter Cashflow
- S&P DJI Announces December 2022 Quarterly Rebalance
- Pause in Trading
- Trading Halt
- Voluntary Suspension
Follow Cogstate into a list and get an email when it puts out news.
Follow Cogstate